A family of ligands has been identified for the largest group of receptor protein-tyrosine kinases -the hitherto 'orphan' EPH receptor subfamilyand the functions of these receptors and ligands are starting to be elucidated.
A characteristic feature of multicellular organisms is that cells communicate with each other to coordinate their activities. This communication is mediated by cellsurface receptors and their ligands. The known receptors fall into several distinct types, each with a characteristic mechanism of transducing an extracellular signal into an intracellular one. One of these major receptor types is the receptor protein-tyrosine kinase type -these receptors have intracellular kinase domains that are activated in response to ligand stimulation, leading to autophosphorylation of tyrosine residues; the phosphorylated tyrosines in turn bind to, and activate, a number of signalling molecules, turning on multiple signalling pathways inside the cell.
The various receptor protein-tyrosine kinases have been divided into subfamilies on the basis of their sequences. The most recent classification [1] delineated 14 distinct subfamilies of receptor protein-tyrosine kinases, including the epidermal growth factor (EGF), platelet-derived growth factor (PDGF), fibroblast growth factor (FGF) and insulin receptors. The largest group is the 'EPH' subfamily, which until recently were ligand-less, 'orphan' receptors. Ligands for EPH-like receptors have, however, now been identified, and constitute a rapidly expanding family of glycosylphosphatidylinositol (GPI)-linked or transmembrane molecules. Elucidation of the functions of these receptor-ligand systems is just beginning, but it seems likely that they play a number of important roles, particularly in the development of the nervous system.
The EPH receptor subfamily EPH subfamily receptors are characterized by an extracellular region that includes an immunoglobulin-like domain, a cysteine-rich sequence that is not related to those in EGF or insulin receptors, and two fibronectin type III repeats. There are 20 cysteines in the extracellular region that are conserved among all the subfamily members. The cytoplasmic region contains a single tyrosine kinase domain and a non-catalytic tail of about 100 amino acids [1] . The prototypical member of this family, EPH, was identified in a human genomic DNA library during a search for gene sequences homologous to the tyrosine kinase domain of the viral oncogene v-fps [2] . Subsequently, several members of this family have been identified from various vertebrate species, including humans, mouse, rat, Xenopus [3] and zebrafish [4] . To date, 13 distinct members of this family have been CELL SIGNALLING discovered, comprising nearly a quarter of all known receptor protein-tyrosine kinases.
Expression of EPH subfamily receptors
Initial clues to the likely functions of proteins discovered on the basis of their gene sequences can come from knowledge of where they are expressed. Several members of the EPH subfamily are predominantly expressed in the adult brain. These include Elk, Eek, Cek4, Cek5, Sek, Ehk-1 and Ehk-2. Other members, however, such as EPH, ECK, HTK, Cek9 and CeklO, have a broader tissue distribution. The tissue distributions of many of the EPH-like receptors have recently been reviewed by Tuzi and Gullick [5] ; three EPH-like receptors not described in that review are Mdkl/Ehk-3/HEK11 [6] [7] [8] , Ehk-2 [9] and HTK/Myk-1 [10, 11] .
Mdkl/Ehk-3/HEK11 is expressed widely in the embryonic brain as well as in a variety of other tissues, including kidney, lung, heart and liver. In the adult, the expression is diminished and more restricted to the brain, testes and spleen [6] [7] [8] . Ehk-2 is almost exclusively expressed in the brain, both in the embryo and in the adult [9] . HTK is widely expressed in the embryo as well as the adult; it is found in fetal heart, lung, liver, kidney and brain. In the adult, HTK is expressed in placenta, kidney, liver, lung, skeletal muscle, heart and pancreas, with no detectable expression in brain. HTK mRNA is also detected in primitive hematopoietic cells and in cell lines derived from myeloid cells, but not in those derived from lymphoid cells [101.
Ligands for EPH subfamily receptors
The first ligand to be identified for an EPH-like receptor was B61, which was found to bind and activate ECK [12, 13] . Since then, several other ligands related to B61 have been discovered by expression cloning, using the extracellular domains of EPH-like receptors expressed as immunoglobulin or alkaline phosphatase fusion proteins to detect ligand expression. Including B61, seven ligands in this family have been identified to date (Fig. 1) . Interestingly, five of the ligands appear to be GPI-linked, whereas the other two have transmembrane domains.
An alignment of the amino-acid sequences of the known ligands for EPH-like receptors is shown in Figure 2 . As suggested by Kozlosky et al. [14] , each ligand molecule can be divided into four regions: a signal peptide, a receptor-binding region, a spacer region and a hydrophobic region (Fig. 1) . The only region of significant identity over the whole family is the receptor-binding region, in which there are four cysteines that are conserved among all known ligands for EPH subfamily receptors. A site for N-linked glycosylation, located near the amino terminus of the mature peptide, is also highly conserved, being present in all EPH-subfamily receptor ligands except LERK-2/Elk-L/EFL-3. Htk L/LERK-5 and AL-1/RAGS, and LERK-3/Ehkl-L/EFL-2 and ELF-1/Cek7 L, contain one and two additional putative N-linked glycosylation sites, respectively. The two transmembrane ligands also show extensive sequence identity in their spacer, hydrophobic transmembrane and cytoplasmic regions. 
Expression of EPH-like receptor ligands
The mRNA expression patterns of the EPH-like receptor ligands are summarized in Table 1 . Most of the data come from northern-blot analyses of whole tissues. It is apparent that, although many of the receptors are restricted in expression to the brain in adults, the ligands seem to have a more widespread expression. As the expression patterns of the ligands are generalized and not restricted to any preferred tissues, no obvious inference can be drawn about their likely roles in vivo. None of the ligand expression patterns exactly matches that of any EPH-like receptor.
It is known, however, that the ligand B61 is an immediateearly response gene in endothelial cells -its expression is induced by proinflammatory factors such as tumor necrosis factor-or (TNF-a), interleukin-1 (IL-1) and lipopolysaccharide (LPS) [13] . The ligand LERK-2 has similarly been shown to be induced by TNF-o in endothelial cells [15] . Whether other ligands are also induced by such proinflammatory factors has not yet been determined.
Biological functions
It is clear from studies in which receptor-binding affinities have been measured that any particular ligand in this family has affinity for many (or all) of the EPH-like receptors. Receptor activation, as measured by autophosphorylation, varies depending upon how the assay is performed. Experiments with artificially clustered, membrane-bound or soluble ligands give differing results, with the former two assay methods tending to show greater activity and promiscuity ( [16] and R.A.L., unpublished observations). Which in vitro assay is the most relevant to function in vivo has yet to be determined. One would assume that both soluble and membrane-bound ligands have physiological functions. The determination of which receptor-ligand pairs are relevant in vivo will therefore depend upon other data, such as colocalization or genetic analyses.
The EPH gene has been shown to have transforming potential when overexpressed in NIH3T3 cells [17] . It has been found to be overexpressed, but not amplified, in a few tumor cell lines [17] . ERK was similarly found to be overexpressed in various tumors of epithelial origin, especially gastric carcinomas [18] . This suggests that overexpression of some of the EPH-like receptors may be involved in oncogenic transformation, as has been seen in the case of many other receptor protein-tyrosine kinases. The activation of a chimeric molecule consisting of the EGF extracellular domain and the Elk transmembrane and cytoplasmic domains, however, did not lead to proliferation of NIH3T3 cells [19] . At present, the data indicate that EPH subfamily receptors do not activate proliferative pathways in cultured fibroblasts or endothelial cells [19, 20] . This may be one of the reasons why identification of signalling pathways in the case of EPH subfamily receptors has been slow compared to other, mitogenic, receptor protein-tyrosine kinases.
As some of the ligands are expressed only when endothelial cells are activated by proinflammatory factors, such as TNF-ot, IL-1 and LPS, it was expected that the activation of EPH subfamily receptors would be involved in certain aspects of inflammation. In this regard, B61 has been shown to induce an angiogenic response in vivo [20] . B61 also induces the migration of endothelial cells [20] , which may be mediated by phosphatidylinositol 3-kinase [21] , an enzyme that has previously been implicated in membrane ruffling and chemotactic responses to ligand stimulation.
The in vivo expression patterns of EPH subfamily receptors and their ligands would suggest that many of them function in the nervous system. Many of the receptors, including Nuk [22] , have been predicted to play a role in axonogenesis. The ligand AL-1/RAGS has recently been shown to affect axonal fasciculation in one in vitro assay [23] , and to induce growth-cone collapse and have axonal repellent activity in another [24] . Axonal guidance and targetting may prove to be one of the major functions of these receptors and their ligands. Elucidation of the functions of these receptor-ligand systems has just begun, but it seems likely that they will turn out to play important roles in the development and maintenance of many cell and tissue types.
